CGON | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 0%

Performance

5 Days

2.98%

1 Month

16.49%

3 Months

35.37%

6 Months

95.70%

1 Year

144.15%

2 Year

40.52%

Key data

Stock price

$60.55

P/E Ratio

0.00

DAY RANGE

$55.50 - $60.69

EPS

N/A

52 WEEK RANGE

$14.80 - $60.69

52 WEEK CHANGE

$125.68

MARKET CAP

2.474 B

YIELD

N/A

SHARES OUTSTANDING

67.077 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-07-2025

BETA

1.43

PUBLIC FLOAT

AVERAGE 10 VOLUME

$854,105

AVERAGE 30 VOLUME

$826,935

Company detail

CEO: Arthur Kuan
Region: US
Website: cgoncology.com
Employees: 0
IPO year: 2024

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

We are a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We were originally founded as a California corporation on September 24, 2010 under the name Cold Genesys, Inc. On November 30, 2017, we reincorporated as a Delaware corporation, and on March 31, 2020, we changed our name to CG Oncology, Inc. Our principal executive offices are located at 400 Spectrum Center Drive, Suite 2040, Irvine, CA.

CGON - CG Oncology, Inc.